Search Result

Results for "

agent-linker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (4) Antibiotic (2) Apoptosis (1) Biochemical Assay Reagents (2) Drug-Linker Conjugates for ADC (128) EGFR (2) Microtubule/Tubulin (14) NAMPT (1) Reference Standards (4) Toll-like Receptor (TLR) (1) Topoisomerase (14)
By Research Areas:	Cancer (130) Infection (1) Inflammation/Immunology (7)
Click Chemistry:	ADC Synthesis (13) TCO (1) DBCO (10) BCN (1) Azide (5) Alkynes (1)

134

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15575

VcMMAE Maximum Cited Publications 92 Publications Verification MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).

HY-100374

Val-Cit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-101070

SMCC-DM1 10+ Cited Publications DM1-SMCC	Drug-Linker Conjugates for ADC	Cancer
SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) .

HY-148820

Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make an antibody agent conjugate (ADC), ABBV-969 .

HY-114233

MC-GGFG-Exatecan 5+ Cited Publications MC-GGFG-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .

HY-145929

MC-Val-Cit-PAB-Exatecan 1 Publications Verification MC-Val-Cit-PAB-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.

HY-148668

MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan SHR-A1811 Drug-linker	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (SHR-A1811 Drug-linker) is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC₅₀=2.2 μM) .

HY-15741

Mc-MMAE Maleimidocaproyl-monomethylauristatin E	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Cancer
Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a agent-linker conjugate for ADC.

HY-136317

MC-betaglucuronide-MMAE-1	Drug-Linker Conjugates for ADC	Cancer
MC-betaglucuronide-MMAE-1 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.

HY-147239

MC-VA-PABC-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-147270

MC-VA-PAB-Exatecan 1 Publications Verification	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-VA-PAB-Exatecan is a agent-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity .

HY-128957

Vc-seco-DUBA 1 Publications Verification Duocarmazine	Drug-Linker Conjugates for ADC	Cancer
Vc-seco-DUBA (Duocarmazine) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco .

HY-116063

Doxorubicin-SMCC 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin .

HY-101141

sulfo-SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.

HY-101162

SGD-1910	Drug-Linker Conjugates for ADC	Cancer
SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala .

HY-126685

Mal-PEG4-VA-PBD	Antibiotic Drug-Linker Conjugates for ADC	Cancer
Mal-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA.

HY-126491

SPP-DM1	Drug-Linker Conjugates for ADC	Cancer
SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP .

HY-128904

MC-Val-Cit-PAB-duocarmycin chloride 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-duocarmycin chloride is a agent-linker conjugate for ADC with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.

HY-135660

MMAE-SMCC	Drug-Linker Conjugates for ADC	Cancer
MMAE-SMCC is a agent-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody agent conjugate.

HY-128968

PEG4-aminooxy-MMAF Amberstatin; AS269	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Inflammation/Immunology Cancer
PEG4-aminooxy-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4 .

HY-153031

Val-Cit-PAB-Exatecan Val-Cit-PAB-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .

HY-141156

Mal-PEG8-Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mal-PEG8-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162) .

HY-139642

Mal-(CH2)5-Val-Cit-PAB-Eribulin	Drug-Linker Conjugates for ADC	Cancer
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB .

HY-126688

Mal-C2-Gly3-EDA-PNU-159682	Drug-Linker Conjugates for ADC	Cancer
Mal-C2-Gly3-EDA-PNU-159682, a agent-linker conjugate for ADC, consists a cleavable ADC linker Mal-C2-Gly3-EDA and a potent ADC cytotoxin PNU-159682.

HY-101152

SG3199-Val-Ala-PAB	Drug-Linker Conjugates for ADC	Cancer
SG3199-Val-Ala-PAB is an intermediate of Tesirine synthesis. Tesirine is a agent-linker conjugate for ADC which can be used for the research of several cancers .

HY-128902

MC-Val-Cit-PAB-vinblastine 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-vinblastine is a agent-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

HY-128955

MC-VC-PABC-Aur0101 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
MC-VC-PABC-Aur0101 is a agent-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.

HY-126681

SC-VC-PAB-MMAE 2 Publications Verification NHS-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-MMAE (NHS-VC-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .

HY-126682

Mal-VC-PAB-DM1 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .

HY-136286

MC-DM1	Drug-Linker Conjugates for ADC	Cancer
MC-DM1 is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody agent conjugate (ADC) .

HY-19811

Fmoc-Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC.

HY-126350

CL2-SN-38 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
CL2-SN-38 is a cleavable linker-based agent-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer .

HY-148194

SC239	Drug-Linker Conjugates for ADC	Cancer
SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-126494

DM4-SMCC	Drug-Linker Conjugates for ADC	Cancer
DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker .

HY-15740

Mc-MMAD	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Cancer
Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a agent-linker conjugate for ADC.

HY-136287

DBM-MMAF 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
DBM-MMAF is a agent-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody agent conjugate (ADC) .

HY-12460

SPDB-DM4 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.

HY-126683

Mal-C6-α-Amanitin 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Mal-C6-α-Amanitin is a agent-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.

HY-132250

MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues .

HY-147286

Ac-Lys-Val-Cit-PABC-MMAE	Drug-Linker Conjugates for ADC	Cancer
Ac-Lys-Val-Cit-PABC-MMAE is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-15575S

VcMMAE-d8 MC-Val-Cit-PAB-MMAE-d₈; mc-vc-PAB-MMAE-d₈	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

HY-15742

Vc-MMAD	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Cancer
Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a agent-linker conjugate for ADC.

HY-132252

Mal-PEG8-Val-Ala-PABC MP-PEG8-Val-Ala-PABC; MP-PEG8-VA-PABC	ADC Linker	Cancer
Mal-PEG8-Val-Ala-PABC is a cleavable Tesirine linker used in the synthesis of Tesirine, a agent-linker conjugate for ADC .

HY-136321

MC-betaglucuronide-MMAE-2	Drug-Linker Conjugates for ADC	Cancer
MC-betaglucuronide-MMAE-2 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.

HY-100566

SuO-Val-Cit-PAB-MMAE 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .

HY-126693

SC-VC-PAB-DM1	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-DM1 is a agent-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB .

HY-148668A

MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC₅₀=2.2 μM) .

HY-130812

Gemcitabine-O-Si(di-iso)-O-Mc	Drug-Linker Conjugates for ADC	Cancer
Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker .

HY-157544

PC5-VC-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
PC5-VC-PAB-MMAE consists the ADCs linker (PC5-VC-PAB) and potent tubulin inhibitor (MMAE). PC5-VC-PAB-MMAE is a agent-linker conjugate for ADC .

HY-152916

mp-dLAE-PABC-MMAE	Drug-Linker Conjugates for ADC	Cancer
mp-dLAE-PABC-MMAE is a agent-linker conjugate for ADC. mp-dLAE-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (HY-15162). mp-dLAE-PABC-MMAE can be used to synthesis antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Type

HY-15578G

McMMAF Maleimidocaproyl monomethylauristatin F	Fluorescent Dye
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-100374G

Val-Cit-PAB-MMAE	Fluorescent Dye
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-42972G

DBCO-acid	Fluorescent Dye
DBCO-acid GMP is a GMP grade DBCO-acid (HY-42972). DBCO-acid is a click chemistry reagent used in the synthesis of ADC linker DBCO-NHS ester ((HY-115524) and (HY-115545)), and agent-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690). DBCO-acid contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

Cat. No.	Product Name	Type

HY-15578G

McMMAF Maleimidocaproyl monomethylauristatin F	Biochemical Assay Reagents
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-100374G

Val-Cit-PAB-MMAE	Biochemical Assay Reagents
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-42972G

DBCO-acid	Biochemical Assay Reagents
DBCO-acid GMP is a GMP grade DBCO-acid (HY-42972). DBCO-acid is a click chemistry reagent used in the synthesis of ADC linker DBCO-NHS ester ((HY-115524) and (HY-115545)), and agent-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690). DBCO-acid contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

Cat. No.	Product Name	Chemical Structure

HY-15575S

VcMMAE-d8
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

Cat. No.	Product Name		Classification

HY-42972

DBCO-acid		ADC Synthesis DBCO
DBCO-acid is a click chemistry reagent used in the synthesis of ADC linker DBCO-NHS ester ((HY-115524) and (HY-115545)), and agent-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690). DBCO-acid contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-134723

DBCO-PEG4-GGFG-Dxd 1 Publications Verification		DBCO ADC Synthesis
DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-148057

TCO-PEG4-VC-PAB-MMAE		ADC Synthesis TCO
TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162) . TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

HY-133492

DBCO-PEG4-MMAF		ADC Synthesis DBCO
DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-133433

DBCO-PEG4-VA-PBD		DBCO
DBCO-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA . DBCO-PEG4-VA-PBD is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-100874

N3-PEG3-vc-PAB-MMAE 4 Publications Verification		ADC Synthesis Azide
N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-111012

DBCO-(PEG)3-VC-PAB-MMAE 3 Publications Verification		ADC Synthesis DBCO
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-W190943

Azido-PEG4-Val-Cit-PAB-MMAE 1 Publications Verification		Azide ADC Synthesis
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-47018

PL1601 BCN-HS-PEG2-VA-PABC-SG3199		ADC Synthesis BCN
PL1601 (BCN-HS-PEG2-VA-PABC-SG3199) is a pyrrolobenzodiazepine that can be used as a agent linker of antibody-drug conjugates (ADC) . PL1601 is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-148194

SC239		DBCO
SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-19812

*Acetylene-linker-Val-Cit-PABC-MMAE* LCB14-0602		ADC Synthesis Alkynes
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a agent-linker conjugate for ADC. Acetylene-linker-Val-Cit-PABC-MMAE is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-126691

DBCO-PEG4-VC-PAB-DMEA-PNU-159682		ADC Synthesis DBCO
DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136261

DM1-PEG4-DBCO		ADC Synthesis DBCO
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136288

Azide-PEG4-VC-PAB-Doxorubicin		Azide
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib		Azide ADC Synthesis
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-136260

DBCO-PEG4-Ahx-DM1		ADC Synthesis DBCO
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-131088A

N3-PEG8-Phe-Lys-PABC-Gefitinib TFA		Azide
N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-42972G

DBCO-acid		DBCO
DBCO-acid GMP is a GMP grade DBCO-acid (HY-42972). DBCO-acid is a click chemistry reagent used in the synthesis of ADC linker DBCO-NHS ester ((HY-115524) and (HY-115545)), and agent-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690). DBCO-acid contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15578G

McMMAF Maleimidocaproyl monomethylauristatin F	Drug-Linker Conjugates for ADC	Cancer
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-100374G

Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-42972G

DBCO-acid	Biochemical Assay Reagents	Cancer
DBCO-acid GMP is a GMP grade DBCO-acid (HY-42972). DBCO-acid is a click chemistry reagent used in the synthesis of ADC linker DBCO-NHS ester ((HY-115524) and (HY-115545)), and agent-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690). DBCO-acid contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: